Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone

1989 ◽  
Vol 25 (2) ◽  
pp. 135-138 ◽  
Author(s):  
Takashi Yoshida ◽  
Shinobu Nakamura ◽  
Shigeki Ohtake ◽  
Kazumi Kobayashi ◽  
Masatoshi Kanno ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Salvage Chemotherapy ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Modified ESHAP as Salvage Chemotherapy for Recurrent or Refractory Non-Hodgkin’s Lymphoma: Results of a Single-Center Study of 32 Patients

Chemotherapy ◽  
2002 ◽  
Vol 48 (5) ◽  
pp. 252-258 ◽  
Author(s):  
Mehmet Akif Öztürk ◽  
İbrahim Barışta ◽  
M. Kadri Altundağ ◽  
Alev Türker ◽  
Şuayib Yalçın ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Salvage Chemotherapy ◽  
Hodgkin's Lymphoma ◽  
Single Center ◽  
Non Hodgkin’S Lymphoma ◽  
Single Center Study ◽  
Non Hodgkin's Lymphoma ◽  
Center Study

Response to Re-Treatment with Rituximab Plus Salvage-Chemotherapy in Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4720-4720 ◽  
Author(s):  
Andrea Borgerding ◽  
Justin Hasenkamp ◽  
Bjoern Chapuy ◽  
Lorenz Truemper ◽  
Gerald Wulf ◽  
...  
Keyword(s):  
Salvage Therapy ◽  
Hodgkin’S Lymphoma ◽  
Progressive Disease ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Salvage Chemotherapy ◽  
Hodgkin's Lymphoma ◽  
Autologous Graft ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract The efficacy of re-therapy with rituximab immuno-chemotherapy was analysed in 20 consecutive patients with relapsed or progressive aggressive Non Hodgkin’s lymphoma after initial treatment with rituximab plus chemotherapy. Ten patients had a diffuse large B-cell lymphoma, seven had a mantle cell lymphoma and three a grade III follicular lymphoma. At primary diagnosis, the IPI was high-intermediate or high in 75% of the patients and the median age was 55 years (range 36–72 years). The overall response rate of primary immuno-chemotherapy was 75% (15/20 patients) with a complete remission in 8/20 patients (40%). After relapse, 53 % of these patients (8/15) responded again to immunochemotherapy: two patients had a second complete and six a second partial remission. None of the five patients with primary progressive disease responded to a conventional immuno-chemo salvage therapy. After re-therapy with rituximab plus salvage chemotherapy, ten patients received at least one cycle of high dose chemotherapy followed by SCT. One patient did receive HD-chemotherapy and an autologous graft solely, two patients did receive HD-radio-immunotherapy followed by an autologous graft and seven patients finally received HDT and an allogeneic transplant. Allogeneic SCT resulted in a CR in 6 out of 7 patients. One of these ten patients relapsed after HDT consolidation. Six out of ten patients without HDT consolidation after immuno-chemotherapy progressed after secondary treatment, 4 patients are alive without progression (SD, PR) but follow up is short (7, 10, 13 and 16 months). Conclusion: A substantial proportion (53%) of patients with relapse after rituximab immuno-chemotherapy did response to rituximab containing salvage therapy. Patients with progressive disease under immuno-chemotherapy did not respond to such salvage therapy. Without additional consolidation by HDT the risk of progression after successful salvage with rituximab and salvage-chemotherapy is high.

Mini-beam as Salvage Chemotherapy for Refractory Hodgkin's Disease and Non-Hodgkin's Lymphoma

1991 ◽  
Vol 5 (2-3) ◽  
pp. 111-115 ◽  
Author(s):  
A. Keith Stewart ◽  
Joseph M. Brandwein ◽  
Simon B. Sutcliffe ◽  
J. Gerald Scott ◽  
Armand Keating
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin’S Disease ◽  
Salvage Chemotherapy ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

Cancer ◽  
1996 ◽  
Vol 77 (11) ◽  
pp. 2302-2307 ◽  
Author(s):  
Aspasia Stamatoullas ◽  
Christophe Fruchart ◽  
Dominique Bastit ◽  
Dominique Boulet ◽  
Mathieu Monconduit ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Salvage Chemotherapy ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Effective salvage chemotherapy in relapsed or refractory non-Hodgkin's lymphoma

1993 ◽  
Vol 4 (3) ◽  
pp. 251-253 ◽  
Author(s):  
R. Buzzoni ◽  
M. Colleoni ◽  
E. Bajetta ◽  
F. Nolè ◽  
P. Nelli ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Salvage Chemotherapy ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Treatment of Primary Progressive Hodgkin’s and Aggressive Non-Hodgkin’s Lymphoma: Is There a Chance for Cure?

2000 ◽  
Vol 18 (2) ◽  
pp. 332-332 ◽  
Author(s):  
Andreas Josting ◽  
Marcel Reiser ◽  
Ulrich Rueffer ◽  
Bernd Salzberger ◽  
Volker Diehl ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Hodgkin’S Lymphoma ◽  
Progressive Disease ◽  
Salvage Chemotherapy ◽  
Salvage Treatment ◽  
Hodgkin's Lymphoma ◽  
Term Survival ◽  
Primary Progressive ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

PURPOSE: To determine differences in prognosis between primary progressive Hodgkin’s disease (HD) and aggressive non-Hodgkin’s lymphoma (NHL), we retrospectively analyzed patients with progressive lymphoma who were treated with different salvage chemotherapy regimens including high-dose chemotherapy (HDCT) followed by autologous stem-cell support (ASCT). PATIENTS AND METHODS: One hundred thirty-one patients with primary progressive lymphoma (HD, n = 67; NHL, n = 64) were enrolled. Primary progressive disease was defined as disease progression during first-line chemotherapy or only transient response (complete or partial response lasting ≤ 90 days) after induction treatment. Patients 60 years or younger with progressive lymphoma were eligible to receive HDCT with ASCT. RESULTS: The overall response rate after salvage chemotherapy for patients with primary progressive HD and NHL was 33% and 15%, respectively. Twenty-five HD patients (37%) received HDCT. Most patients with NHL had progressive disease under salvage treatment, with only six patients (10%) receiving HDCT. Of those, only two patients were alive and in continuous complete remission 3 and 12 months after HDCT. No patient with NHL survived longer than 26 months after first diagnosis. Actuarial OS after 5 years was 19% for all HD patients; 53% for HD patients receiving HDCT, and 0% for patients who did not receive HDCT. In HD patients, multivariate regression analysis identified chemosensitive disease on salvage treatment (P = .0001) and HDCT (P = .031) as significant prognostic factors for freedom from treatment failure. Significant prognostic factors for OS are chemosensitive disease (P = .0005), HDCT (P = .039), and B symptoms at the time of progress (P = .046). CONCLUSION: There are striking differences in the prognosis of patients with progressive HD and aggressive NHL. The prognosis of progressive NHL patients is dismal. Most patients have rapidly progressive disease after salvage treatment and are, therefore, excluded from HDCT programs. In contrast, progressive HD patients can achieve long-term survival after HDCT.

Sign in / Sign up

Export Citation Format

Share Document